Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR.

A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay ...